2655787D

2655787D — 13F Holders Deep Dive

Blueprint Medicines CORP

-$2.5M

Net Activity

Institutions Holding

Popularity Rank

#16907

Avg Weight

0.01%

Total Value

$38.6K

Ownership Trend

2 institutions currently hold 2655787D, with 1 net buyers and 2 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Decreased

Based on recent trading activity

Net Selling Institutions

Net Buying Institutions

Key Holders

Top 5 by Value

Kelleher Financial Advisors

$38.5K

Huntington National Bank

$129.0

Top 5 by Conviction

Kelleher Financial Advisors

0.01%

Huntington National Bank

0.00%

View all 2 holding institutions

Quarterly Activity

Recent Activity

+$38.5K

Total Buy Value

$3.4M

Total Sell Value

New buy1

Trim0

Add0

Sold out2

Net Buyers

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding BLUEPRINT MEDICINES CORP (2655787D)?

Major stakeholders currently include Kelleher Financial Advisors ($38.5K), Huntington National Bank ($129.0). Based on the latest 13F filings, there are a total of 2 tracked investment funds and institutions maintaining positions in 2655787D.

What is the overall institutional sentiment toward 2655787D recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $2.5M, driven by 1 managers accumulating shares while 2 reduced their exposure.

Which institutions have been selling or reducing their 2655787D positions?

In the latest period, 0 funds trimmed their holdings, and 2 managers completely exited their positions. The aggregate reported sell value was $3.4M.

Are there any notable investors adding 2655787D to their portfolios?

Yes, buying activity remains notable. 1 institutions opened new positions in {ticker}, and 0 existing holders added to their shares. The total reported buy value for the quarter amounted to $38.5K.